Diabetes Mellitus, Type 2
Conditions
Brief summary
A study to assess the effectiveness and tolerability of MK0653A and MK0653A versus Atorvastatin in lowering LDL-C levels.
Interventions
Sponsors
Organon and Co
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Currently being treated with Atorvastatin 10 mg for at least 6 weeks * Have Type 2 Diabetes * Weight must be stable for more than 6 weeks before entering the study
Exclusion criteria
* Consume more than 14 alcoholic drinks per week. * Pregnant or lactating * Have taken another investigation drug within 3 months of starting this study * History of congestive heart failure, heart attack, coronary artery bypass surgery * Uncontrolled high blood pressure * HIV positive * History of cancer in the last 5 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the additional LDL-C lowering achieved by switching to MK0653A as compared to Atorvastatin after 6 weeks of treatment | 6 Weeks |
Secondary
| Measure | Time frame |
|---|---|
| Determine the effect of MK0653A versus Atorvastatin on total cholesterol after 6 weeks of treatment | 6 Weeks |
Outcome results
None listed